Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01548768 · ClinicalTrials.gov registry record · Phase 4

RHYTHM (Formerly Escape II Myocardium)

A Phase 4 study, sponsored by Columbia University.

Completed
Registry status
Phase 4
Development phase
149
Enrollment target

NCT01548768 is a Phase 4 study that has completed, run by Columbia University. The registered enrollment target is 149 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01548768, a Phase 4 study, has completed, sponsored by Columbia University.

COMPLETED
Registry status
Phase 4
Development phase
149 participants
Enrollment target

Study Summary

For aim 1, the proposed studies will be performed in 150 patients with RA and 25 subjects without RA (healthy volunteers) who will function as controls. For aim 2, 25 of the patients enrolled in aim 1 (who are in need for further treatment due to increased RA activity despite their current treatment) will be recruited to continue in the study for an additional 24 (+/- 2) weeks (or 6 months). These patient will receive a TNF inhibitor in addition to their current treatment in an open label protocol for increased disease activity and in the context of standard of care. The investigators hypothesize that anti-TNF agents in RA patients without heart disease will not adversely affect the heart (will not cause a detrimental change in heart structure or its function).

Interventions

  • DRUG TNF inhibitors
  • DRUG DMARDs

Trial Details

FieldValue
Enrollment Target 149 participants
Start Date 2011-10-10
Est. Completion 2019-09
Phase Phase 4

Sponsor

Columbia University

958 total trials

What the Registry Record Tells You About NCT01548768

The ClinicalTrials.gov registry entry for NCT01548768 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 149 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which TNF inhibitors is the first listed.

NCT01548768 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01548768 about?

NCT01548768 is a clinical study titled "RHYTHM (Formerly Escape II Myocardium)". For aim 1, the proposed studies will be performed in 150 patients with RA and 25 subjects without RA (healthy volunteers) who will function as controls. For aim 2, 25 of the patients enrolled in aim 1 (who are in need for further treatment due to increased RA activity despite their current treatmen...

What is the current status of trial NCT01548768?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 149 participants. The study started on 2011-10-10. Estimated completion is 2019-09.

What interventions are being tested in trial NCT01548768?

The interventions under investigation include: TNF inhibitors (DRUG), DMARDs (DRUG).

Who is sponsoring clinical trial NCT01548768?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.